LFB is a French biopharmaceutical group that develops, manufactures and commercializes/ markets medication for serious and often rare pathologies in the following major therapeutic fields: immunology, intensive care and hemostasis. The LFB group is number one in France and number five in the world in plasma-derived medicinal products. The group is also one of the top European companies in the development and production of proteins and new generation treatments in biotechnologies. In 2012, 76.7 million euros were put towards research and development, for a turnover of 465.7 million euros. Christian Béchon is the President of the group, which has 1887 employees.
to get access to their Product
Catalog and their Product Environmental Footprints.
Are you working with
to reduce your value chain
scope 3 emissions? If not, consider starting to do so today